...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Usually holdings by funds are not available real time to us "small" investors.
Those holdings get updated periodically, at least once a month, I think.
That is what he meant to say - we can expect updates to that list. By the time we get to know it, it does not matter - it will be in the past.
Again, because hedge funds are not regulated, I do not believe they can or need to show their holdings.
I do know that Mutual funds (and Pension funds) cannot touch stocks below $5.
Hedge funds are unregulated and can do what they please.
Someone more knowledgeable - please correct me if I am wrong.
There are several Longs who really believe in this company and will not sell for a small jump in price - most of the Longs are expecting this company to be in the $ range after we get a real PR from the company regarding PSA test.
No doubt - all this volume is external to iHub. Also, retail investors do not have the deep pockets to drive this kind of surge in volume.
Most likely they are institutional funds.
One would expect, with such a volume and interest, the MMs would let this run. Something else is holding this down.
This stock is unique in its trading!
ha ha - that would be something.
Many of the day traders are probably out at that shake earlier.
Let's see today if we can close around .35-.37
We have good volume.
5 million in a little over an hour - is darn good!
Here comes the shake that will separate the Longs from the Day traders.
Yes - liked that part - "company would likely not have much to say for "at least a few days" due to the nature of some "very sensitive non-disclosure agreements that are in place with both existing and potential partners."
- assuming that is true - we are in for a ride!
Yes - liked that part - assuming that is true - we are in for a ride!
Thank you for confirming that...
Check out some of the slides they have in that biomed report - that HDVY had "supposedly" shown at the conference...
Use this url and click on the slide show...
biomedreports.com/articles/most-popular/26924-hdvy-development-update.html
They show how market responded to VRML molecular diagnostic test and how HDVY was involved in that test.
Looks like the slides set is incomplete but you get the idea...
That is what I would conclude TSBob.
Retail traders cannot create such volume ... in such a short time.
Good for us
Yes - we have good volume to start out today.
I wonder if the MMs are holding this down - in anticipation of PR news from HDVY.
I rely more on charts than L2.
Since I am LONG - daily PPS changes should not matter.
There are so many on this board who have been patiently waiting ... for the PR to break out to the $ ranges...
There are some statements in the above Biomed report that appear to be very interesting.
IF what is stated in that report is indeed true, we really might have a good PR coming out soon from HDVY.
Not that I follow BioMed - but saw this link in Yahoo msg board...
biomedreports.com/articles/most-popular/26924-hdvy-development-update.html
Health Discovery Corporation (OTC:HDVY) Developments Update
Written by Peter DePalma
Monday, 01 February 2010 00:00
Record interest in Health Discovery Corporation (OTC:HDVY) continues. Is the company on the verge of a major development? This weekend, we were able to track down a company official who, while very gracious, said that company would likely not have much to say for "at least a few days" due to the nature of some "very sensitive non-disclosure agreements that are in place with both existing and potential partners."
Under condition of anonymity, however, the representative was able to confirm to BioMedReports that there was "significant response" to last week's presentation in Dallas. "It was much more significant than the response we had during our presentation at the end of October in Philadelphia," said the source.
As we reported to our subscribers last week, HDVY made a presentation in front of a nationwide network of independent broker/dealers, investment bankers and other finance leaders at the FSX Conference which took place at the Ritz Carlton Hotel in Dallas. Friday, the company experienced a record day in trading volume and shares rose over 25%- trading as high as $.31 before closing out the session at $.276.
Some slides from HDVY's recent presentation to bankers and brokers in Dallas (click icon in the bottom right center of the player to watch full-screen):
Activity and volume for the stock had increased during the past two sessions after speculation that one of HDVY's diagnostic tests for prostate cancer may finally be ready for commercialization. If those rumors are true, then shares of the company could rise dramatically upon official confirmation- especially since such news would signal a paradigm shift in the way men are screened for prostate cancer not only in the U.S., but around the world.
The most current and common screening test for prostate cancer used today misses up to 82% of cancers in men younger than 60 and 65% in those older than 60, according to a past study in the New England Journal of Medicine.
That blood test, known as prostate-specific antigen, or PSA, is used in an attempt by most doctors detect early prostate cancer, but studies have found that results tend to trigger a biopsy in far too many cases.
One of the most famous cases involves one-time Democratic presidential candidate John Kerry, who had a PSA reading of 3.4- which doctors consider within the "normal" range. His wife noted that the reading was slightly elevated from a previous test and she urged him to go in for more testing. Sure enough, cancer was found and he had to have his prostate removed.
So why all the excitement and interest in HDVY's various tests and related technologies?
According to some of the information which was presented in Dallas and obtained by BioMedReports the company claims that their various Molecular Diagnostics Tests:
* Detect disease at an earlier stage
* Enable the selection of optimal therapy
* Reduce trial-and-error prescribing
* Reduce adverse drug reactions
* Increase patient compliance with therapy
* Improve the selection of targets for drug discovery
* Reduce the time, cost, and failure rate of clinical trials
* Reduce the overall cost of healthcare
Information presented at the conference indicates that Health Discovery Corporation's new urine based molecular diagnostic test for prostate cancer has co-exclusive royalty bearing licenses with Abbot, Quest Diagnostics and Clarient. HDVY is set to receive payments, royalties and additional undisclosed financial considerations from the commercialization of the tests.
The PSA test has been heavily criticized in Academic Institutions and the media for it’s poor performance in the recent peer-reviewed publication in the New England Journal of Medicine.
In March of 2009, a US study concluded that after following men for a decade, those screened annually with the PSA or a rectal exam were no more likely to avoid death from prostate cancer than those tested less frequently or not at all.
"I'm 50 times more likely to receive unnecessary treatment than I am to be the one who avoided the prostate cancer death," said Dr. H. Gilbert Welch, a Department of Veterans Affairs researcher in White River Junction, Vt., who studies the consequences of cancer screening. "From my perspective, that's not a very good gamble."
"These studies make it difficult to have a one-size-fits-all recommendation," said Dr. Michael Barry, of Massachusetts General Hospital to the Boston Globe. Barry has extensively studied prostate cancer screening and points out that: "If a man has his eyes open and knows the risks and knows what the trade- offs are, he may either want or not want the PSA."
Since its adoption in the late 1980s, PSA testing has been bolstered by studies showing that prostate deaths overall were declining. Testing was sometimes given credit, but at the same time that screening was becoming more widespread, treatments for the disease were improving.
But those treatments can leave a man impotent or incontinent without any guarantee that a tiny tumor lodged in the prostate would ever have threatened his life.
The lead author of that US study, Dr. Gerald Andriole, said he hoped the studies will "temper those sort of knee-jerk responses" that have led to men with positive PSA tests being rushed into the operating room.
"PSA and the fear of prostate cancer are absolutely ingrained in Western societies," said Andriole, chief of urologic surgery at Washington University in St. Louis. "If we could have a very candid conversation with patients who have very tiny tumors, maybe we could spare them the side effects of aggressive treatment of prostate cancer."
The current PSA test shows sensitivity of 70%-80% and a Specificity of 60%-70%.
HDVY's prostate cancer tests showed 90% Sensitivity for correctly identifying the presence of Grade 3 or higher prostate cancer cells and 97% Specificity for correctly identifying non-cancer cells (normal and BPH).
The current market statistics show that 50 million PSA’s are performed worldwide annually. The price of these PSA tests in the US is approximately $100 per test - which represents a $5 billion market.
Speculators appear to be betting that HDVY's new prostate cancer test is not only about to be commercialized, but that it has a very good chance of replacing the current PSA test for multiple reasons, including the fact that Health Discovery Corporation's urine based prostate cancer test is non-invasive (only requiring a urine specimen), while the PSA test requires an invasive blood collection procedure.
This needs to stay above .28 for a sustained move up.
Let's see how it holds up today.
I share a similar view - that it is not these outfit's new "Buy" recommendation. Instead, it is the "serious money" (of Institutional buyers) that are trying to position themselves ahead of expected news.
Chart timing is perfect for this expected run up.
This week should be very interesting to watch.
Another bullish chart confirmation - from AmericanBulls.com
www.americanbulls.com/StockPage.asp?CompanyTicker=HDVY&MarketTicker=OTC&TYP=S
Nebula and Claytrader are of the same opinion.
Looks good to me
I seriously doubt if BioMed reports could act as a catalyst to drive a record 12 million trading volume on this company.
Something else is going on. In my past experience, usually it is the institutional investors that can create such liquidity and trading volume.
I do not follow BioMed reports - nor do I want to.
Chart indicators look primed for a bullish surge next week.
Should be fun to watch!
This link does not indicate what happened during the conference at Dallas. However, I can confirm that HDC (our company HDVY) does show up in the list of presenters.
See this link - 3rd column about midway is the company HDC, and when you click on it, it takes you to HDVY website.
www.fsx1.com/fsx/PresentingCompanies/LatestPresenters/tabid/101/Default.aspx
You can also see a Photo vault of what happened during the conference - I could not see anything/anyone about HDVY. Perhaps others can check it out?
Here's the link -
www.fsx1.com/fsx/FSXConferences/ConferencePhotos/Dallas2010Photos/tabid/118/Default.aspx
What would be great is, if we could find an audio link to that conference - but I doubt it it is accessible. I could not find it in the FSX website.
Cheers
True - I don't follow them. I would expect some pull back from the folks who want to take advantage of the run. But if the volume is more than a million shares, I doubt if it will have an impact.
Chart is looking good - MACD, pSAR, PPO, ADX and all the averages.
My near term expectation is that we continue climbing a few more days, break out the .42 ceiling and consolidate there.
Nobody knows what will happen. Let's see how it turns out.
Yeah, stay Long and prosper.
We sure can hope - none of us expected today's record volume.
Yesterday's bullish engulfing candle was a good omen.
Let's see how the next week shapes up.
Have a good weekend.
Incredible -- record 12 million volume.
Good luck to all the longs...
I am holding and NOT plan to sell for such a small pop - to each his/her own.
This is a long term hold for me....like many others - we expect this to be much higher.
Yes - in the big scheme of things, 3 million dollars is chump change for these institutional funds.
This company is not a pinky!
It is fully transparent and reporting company in the OTC BB.
As more funds become aware of it, they would want to be in the "personalized medicine" niche - this company is one great deal to be in.
This is not a day trading stock in my portfolio....
Exactly - record volume - totally unexpected!
Get some rest Bob.
heh heh - I am too excited - it's been a while since this company got the attention it deserved.
Like many others holding this, we have been very patient...
Thanks Nebula - I have L2 - but I don't pay too much attention to it.
Hi TSBob - hope you are ok after your surgery.
Approaching record 10 million volume today - looks like institutional investors are getting on board.
There was a investment conference in Dallas where many institutional funds showed up and became aware of HDVY.
2 outfits - Liberty Analytics & BioMedReports issued an alert, with a follow up report on Monday from the latter.
Cheers
If not the MMs, is it the hedgies? Would you happen to know?
Can't figure out why the MMs are holding this down - approaching a record 10 million volume!
.28-.29 wall took a while to break ... now let's not see those 20s again!
More investors will get educated ... we know that today's heavy volume is likely from institutions getting on board...
heh heh - I would not expect a VRMLQ type of response. The dynamics in that stock was different (I did not play it).
Yeah - must be the full moon!
True - it's been a while - the patient holding from the lows will be well worth it.
Cheers
Here we go ... let's go for the next ceiling at .40 --- good day to break that on EXTREME heavy volume
I would change the "IF" to a "When" - with all the patents and technologies that HDVY has
Right "choo choo trader" - HDVY has so many patents and technologies in its arsenal - this is a long term hold for me.
Good consolidation near the highs - now for the next leg up...
7 million! Looks like the hedge funds and other institutions are slowly becoming "aware" of this company.
Recent conferences are helping this trend.